BiotechTube
Home/Sandoz/Glenn D. Gormley, MD, PhD
GD

Glenn D. Gormley, MD, PhD

Chairman of the Board

Sandoz

Therapeutic Areas

OncologyImmunologyAnti-infectivesOphthalmologyCentral Nervous SystemCardiovascularDermatology

Sandoz Pipeline

DrugIndicationPhase
Biosimilar DenosumabOsteoporosis, Bone Loss (Prolia/Xgeva)Regulatory Review
Biosimilar NivolumabVarious Cancers (Opdivo)Phase III
Biosimilar PembrolizumabVarious Cancers (Keytruda)Phase III
Biosimilar DupilumabAtopic Dermatitis, Asthma (Dupixent)Phase III
Biosimilar UstekinumabPsoriasis, Crohn's Disease (Stelara)Phase III
Biosimilar AfliberceptOphthalmology (Eylea)Phase III

Leadership Team at Sandoz

RS
Richard Saynor
Chief Executive Officer
RS
Remco Steenbergen
Chief Financial Officer
KH
Keren Haruvi
President, Sandoz North America
PB
Pierre Bourdage
President, Sandoz International
RG
Rebecca Guntern
Head of Strategy & Innovation
View full Sandoz profile